Seastar medical holding corp
ICU 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
ICU 近期報酬表現
-22.79%
Seastar medical holding corp
-0.98%
同產業平均
-0.22%
S&P500
與 ICU 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
OLK | Olink holding ab (publ) | - | 1 分 | 2 分 | 2 分 | 1 分 | |
IRIX | Iridex corp | 4 分 | 4 分 | 2 分 | 1 分 | 1 分 | |
ACON | Aclarion inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
NUWE | Nuwellis inc | 2 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
IART | Integra lifesciences holdings corporation | 4 分 | 1 分 | 2 分 | 2 分 | 1 分 |
- OLK Olink holding ab (publ)價值 -趨勢 1 分波段 2 分籌碼 2 分股利 1 分查看更多
ICU 公司資訊
SeaStar Medical Holding Corporation is a medical technology company. The Company is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The Company's technologies rely on science to provide life-saving solutions to critically ill patients. The Company develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It uses its proprietary Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.